FDA black box warning on the use of 80 mg simvastatin: Difference between revisions
Kashish Goel (talk | contribs) No edit summary |
Kashish Goel (talk | contribs) No edit summary |
||
Line 11: | Line 11: | ||
* New contraindications and dose limitations added to the label for use with other medications. | * New contraindications and dose limitations added to the label for use with other medications. | ||
:'''Change in Simvastatin label''' | |||
:{| class="wikitable" border="1" | |||
|+ | |||
! Previous Simvastatin label !! New Simvastatin label !! | |||
|- | |||
| Avoid simvastatin with:<br>Itraconazole<br>Ketoconazole<br>Erythromcyin<br>Clarithromycin<br>Telithrromcyin<br>HIV protease inhibitors<br>Nefazodone || Contraindicated with simvastatin:<br>Itraconazole<br>Ketoconazole<br>Posaconazole (new)<br>Erythromcyin<br>Clarithromycin<br>Telithrromcyin<br>HIV protease inhibitors<br>Nefazodone<br>Gemfibrozil<br>Cyclosporine<br>Danazol || | |||
|- | |||
| ''Moderately high risk''<br>2+ risk factors (10-year risk 10% to 20%) || <130 mg/dL || ≥ 130 mg/dL || 100-129 mg/dL | |||
|- | |||
| ''Moderate risk''<br>2+ risk factors (10-year risk <10%) || <130 mg/dL || ≥ 130 mg/dL || ≥ 160 mg/dL | |||
|- | |||
| ''Lower risk''<br>0-1 risk factors || <160 mg/dL || ≥ 160 mg/dL || 160-189 mg/dL | |||
|}<br><br><br> | |||
==References== | ==References== |
Revision as of 20:50, 14 September 2011
Template:Hypercholesterolemia
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-632-7753; Associate Editor(s)-In-Chief: Kashish Goel, M.D.
Overview
Simvastatin 80 mg is the highest approved dose for this drug and it is estimated that approximately 2.1 million patients in the U.S. were prescribed this dose in the year 2010. In March 2010, FDA revised the simvastatin label and recommended that patients of Chinese descent should not receive simvastatin 80 mg with cholesterol-modifying doses of niacin-containing product. This review was based on the interim results of Heart Protection Study. On 8th June 2011, FDA added another black box warning to the use of high dose simvastatin. Based on the review of randomized clinical trial, Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH), FDA recommended limiting the use of high-dose simvastatin. Following recommendations were given:
- Simvastatin 80 mg should not be started in new patients, including those who are taking lower doses.
- This dose should be used only in those who have taken this medication for more than 12 months without any evidence of myopathy.
- New contraindications and dose limitations added to the label for use with other medications.
- Change in Simvastatin label
Previous Simvastatin label New Simvastatin label Avoid simvastatin with:
Itraconazole
Ketoconazole
Erythromcyin
Clarithromycin
Telithrromcyin
HIV protease inhibitors
NefazodoneContraindicated with simvastatin:
Itraconazole
Ketoconazole
Posaconazole (new)
Erythromcyin
Clarithromycin
Telithrromcyin
HIV protease inhibitors
Nefazodone
Gemfibrozil
Cyclosporine
DanazolModerately high risk
2+ risk factors (10-year risk 10% to 20%)<130 mg/dL ≥ 130 mg/dL 100-129 mg/dL Moderate risk
2+ risk factors (10-year risk <10%)<130 mg/dL ≥ 130 mg/dL ≥ 160 mg/dL Lower risk
0-1 risk factors<160 mg/dL ≥ 160 mg/dL 160-189 mg/dL